|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|
| Revenue: | ||||
| Revenue | ||||
| Service revenue | ||||
| Royalty and other revenue | ||||
| Collaborative arrangement revenue | ||||
| Total revenues | ||||
| Operating expenses: | ||||
| Research and development | ||||
| Cost of manufacturing for commercial collaboration | ||||
| Selling, general and administrative | ||||
| Share of collaboration loss | ||||
| Restructuring expenses | ||||
| Cost of royalty and other revenue | ||||
| Change in fair value of contingent consideration | ||||
| Goodwill impairment charge | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Interest income, net | ||||
| Other income, net | ||||
| Gain (loss) on sale of assets | ||||
| Novo | ||||
| Regeneron | ||||
| Loss before income taxes | ||||
| Income tax expense | ||||
| Net loss | ||||
| Net loss per share - basic (in dollars per share) | ||||
| Net loss per share - diluted (in dollars per share) | ||||
| Weighted-average number of common shares used in computing net loss per share - basic | ||||
| Weighted-average number of common shares used in computing net loss per share - diluted | ||||
| Other comprehensive income: | ||||
| Other comprehensive income, net of tax benefit (expense) of $0.0 million and $0.0 million for the years ended December 31, 2024 and 2023, respectively. | ||||
| Comprehensive loss |
Loading...
